Stockscreener 앱 받기
7.68
0.26%
-0.02
Gyre Therapeutics Inc 주식(GYRE)의 최신 뉴스
Setup Watch: What dividend growth rate does Gyre Therapeutics Inc offer2025 Winners & Losers & Community Verified Trade Alerts - baoquankhu1.vn
Tech Rally: Is TRTNPRC stock a value trapWeekly Risk Report & Stock Portfolio Risk Management - baoquankhu1.vn
Market Pulse: Will Gyre Therapeutics Inc outperform tech stocksJuly 2025 Summary & Expert-Curated Trade Recommendations - baoquankhu1.vn
Ideas Watch: What are analysts price targets for Gyre Therapeutics IncIPO Watch & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Gains Report: How Gyre Therapeutics Inc stock valuations compare to rivalsJuly 2025 Sentiment & Weekly Stock Breakout Alerts - Bộ Nội Vụ
How Gyre Therapeutics Inc. stock compares to growth peersTrade Risk Assessment & Safe Entry Point Alerts - Улправда
Aug Big Picture: Will Gyre Therapeutics Inc stock benefit from commodity pricesJuly 2025 Closing Moves & Reliable Intraday Trade Alerts - Bộ Nội Vụ
Will Dynagas LNG Partners LP stock deliver consistent dividends2025 Breakouts & Breakdowns & Verified Short-Term Plans - Улправда
What margin trends mean for Mach Natural Resources LP stockSwing Trade & Capital Efficiency Focused Ideas - Улправда
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.7%Time to Sell? - MarketBeat
Gyre Therapeutics, Inc. Announces Completion of the Pre-NDA Meeting on the Regulatory Strategy for F351 - marketscreener.com
GNI Group’s F351 Secures Path Toward Conditional Approval and Priority Review in China - TipRanks
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap UpShould You Buy? - MarketBeat
Gyre Therapeutics stock soars after positive pre-NDA meeting in China - Investing.com Nigeria
Gyre Therapeutics stock soars after positive pre-NDA meeting in China By Investing.com - Investing.com South Africa
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Gyre Pharmaceuticals advances liver fibrosis drug toward China approval By Investing.com - Investing.com Canada
Gyre Therapeutics Announces Pre-NDA Meeting Success for Hydronidone - TradingView — Track All Markets
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting - The Manila Times
Experimental liver fibrosis drug in China moves closer to patient use - Stock Titan
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Rating of "Hold" by Analysts - MarketBeat
Info Edge (India) Limited Stock Approaches Key Moving AverageLong-Term Growth Stocks & High Profit Market Ideas - bollywoodhelpline.com
Gyre Therapeutics president sells $45,380 in stock - MSN
Industries Limited (511034) Hits 52 Week HighSwing Trading Ideas & Build Diversified Portfolios With Ease - bollywoodhelpline.com
Undiscovered Gems in the US Market to Explore This December 2025 - Yahoo Finance
Published on: 2025-12-21 18:19:37 - Улправда
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 3.6% – Time to Sell? - Defense World
Noble Financial Sticks to Their Buy Rating for Greenwich LifeSciences (GLSI) - The Globe and Mail
Will Gyre Therapeutics Inc. stock keep outperforming rivalsJuly 2025 Breakouts & Low Drawdown Investment Strategies - Улправда
Gyre Therapeutics Earnings Notes - Trefis
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 3.6%Time to Sell? - MarketBeat
Why Gyre Therapeutics Inc. stock remains on buy lists2025 Trading Recap & Long-Term Capital Growth Strategies - Улправда
Levels Update: Is Gyre Therapeutics Inc. stock vulnerable to regulatory risks2025 Major Catalysts & Weekly Momentum Picks - Улправда
Will Gyre Therapeutics Inc. stock deliver consistent dividends2025 Market WrapUp & Reliable Price Action Trade Plans - Улправда
Does Gyre Therapeutics Inc. stock trade at a discount to peers2025 Geopolitical Influence & AI Driven Price Forecasts - Улправда
Gyre therapeutics president Ma Songjiang sells $45,434 in stock - MSN
US High Growth Tech Stocks to Watch - Yahoo Finance
Gyre Therapeutics president Ma Songjiang sells $42,480 in stock - MSN
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 5.9%Should You Sell? - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Recommendation of “Hold” from Brokerages - Defense World
GNI Group’s Subsidiary Completes Enrollment for Key Clinical Trial - MSN
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 2.3%Time to Buy? - MarketBeat
Gyre Therapeutics (GYRE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Gyre Therapeutics Stock Built to Withstand a Pullback? - Trefis
Regarding video postings related to our company group information on some social networking services (SNS). - 富途牛牛
Published on: 2025-11-27 08:38:09 - moha.gov.vn
Is Gyre Therapeutics Inc a good long term investmentMarket Depth Overview & Free Unmatched Market Performance - earlytimes.in
Is Gyre Therapeutics Inc. stock a dividend growth opportunity2025 Short Interest & Real-Time Volume Triggers - newser.com
Is Gyre Therapeutics Inc. stock dividend yield sustainableJuly 2025 Closing Moves & Safe Entry Point Identification - newser.com
What drives Gyre Therapeutics Inc stock priceMarket Capitalization Trends & Free Triple Digit Wealth Increase - earlytimes.in
Will Gyre Therapeutics Inc. stock return to pre crisis levelsLong Setup & Low Risk High Win Rate Picks - newser.com
Should I hold or sell Gyre Therapeutics Inc. stock in 2025July 2025 Final Week & Verified Technical Signals - newser.com
Why Gyre Therapeutics Inc. stock remains on watchlistsMarket Activity Report & Weekly Chart Analysis and Guides - newser.com
4.73%
0.92%
자본화:
|
볼륨(24시간):